Ákos Iliás - Concepedia

Author

Ákos Iliás

Semmelweis University ORCID

Also Known As

A Ilias, A Iliás, A. Ilias, Akos Ilias, Amina Ilias, Audu Ilias, Á Iliás, Ákos Iliás

Publications

410

Citations

H-Index

Concepts

All Affiliations

Semmelweis University McGill University Health Centre University of Szeged University of Pecs Montreal General Hospital

ÁI

About

Ákos Iliás is an author at Semmelweis University specializing in medicine, gastroenterology, and outcomes research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	76
2	Engineering	1	1	168
3	Public Health	1	1	12
4	Civil Engineering	1	1	168
5	Construction Engineering	1	1	168

Ákos Iliás

Publications

326

Citations

H-Index

Page 1

	Year	Citations
A study on the parameters affecting the properties of Portland limestone cements S. Tsivilis, Emmanouil Chaniotakis, Efstratios Badogiannis, Cement and Concrete Composites Geotechnical EngineeringCementationEngineeringCivil EngineeringMechanical Engineering	1999	168
Melkersson‐ Rosenthal's syndrome in four generations C. Lygidakis, C. Tsakanikas, Ákos Iliás, Clinical Genetics	1979	45
Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade Ákos Iliás, K Szántó, Lóránt Gönczi, Clinical Gastroenterology and Hepatology Translational MedicineGastroenterologyOutcomes ResearchClinical GastroenterologySurgery	2019	34
Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study Livia Lontai, Lóránt Gönczi, F Balogh, Digestive and Liver Disease Multicentre StudyImmunologyClinical GastroenterologyUlcerative ColitisMedicine	2022	16
Incidence, Predictive Factors, Clinical Characteristics and Outcome of Non-variceal Upper Gastrointestinal Bleeding – A Prospective Population-based Study from Hungary Lóránt Gönczi, Livia Lontai, F Izbéki, Journal of Gastrointestinal and Liver Diseases	2021	15
Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab – A prospective, multicenter cohort from Hungary Lóránt Gönczi, K Szántó, Klaudia Farkas, Digestive and Liver Disease Gastrointestinal PharmacologyMedicineGastroenterologyDrug SustainabilitySerum Drug Levels	2021	14
Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies Lóránt Gönczi, Zsuzsanna Kürti, Petra A. Golovics, Digestive and Liver Disease Health Care DeliveryHealth PolicyOpen AccessGastroenterologyOutcomes Research	2017	12
Ustekinumab is associated with superior treatment persistence but not with higher remission rates <i>versus</i> vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study Péter Bacsúr, Mária Matúz, Tamás Resál, Therapeutic Advances in Gastroenterology	2022	12
Burden of perianal disease in Crohn's disease: Accelerating medical therapy and high rates of perianal surgery over the last four decades – Results from a population‐based study over four decades Lóránt Gönczi, Petra A. Golovics, Dorottya Angyal, Alimentary Pharmacology & Therapeutics	2023	10

Page 1